MX2024009969A - Formulacion liquida de toxina botulinica y uso de la misma. - Google Patents

Formulacion liquida de toxina botulinica y uso de la misma.

Info

Publication number
MX2024009969A
MX2024009969A MX2024009969A MX2024009969A MX2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A MX 2024009969 A MX2024009969 A MX 2024009969A
Authority
MX
Mexico
Prior art keywords
botulinum toxin
liquid formulation
relates
present
agent
Prior art date
Application number
MX2024009969A
Other languages
English (en)
Spanish (es)
Inventor
Claudia Jatzke
Klaus Fink
Karl- Heinz Eisele
Harold V Taylor
Katja Kühbach
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2024009969A publication Critical patent/MX2024009969A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51Chelating agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
MX2024009969A 2022-02-15 2023-02-14 Formulacion liquida de toxina botulinica y uso de la misma. MX2024009969A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22156850 2022-02-15
PCT/EP2023/053634 WO2023156385A1 (en) 2022-02-15 2023-02-14 Liquid botulinum toxin formulation and use thereof

Publications (1)

Publication Number Publication Date
MX2024009969A true MX2024009969A (es) 2024-09-18

Family

ID=80682748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009969A MX2024009969A (es) 2022-02-15 2023-02-14 Formulacion liquida de toxina botulinica y uso de la misma.

Country Status (13)

Country Link
US (1) US20250161186A1 (https=)
EP (1) EP4479012A1 (https=)
JP (1) JP2025504247A (https=)
KR (1) KR20240150786A (https=)
CN (1) CN118829442A (https=)
AR (1) AR128515A1 (https=)
AU (1) AU2023222384A1 (https=)
CA (1) CA3243198A1 (https=)
CO (1) CO2024010938A2 (https=)
IL (1) IL314995A (https=)
MX (1) MX2024009969A (https=)
TW (1) TW202400223A (https=)
WO (1) WO2023156385A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192118A (ja) * 1992-09-28 1994-07-12 Wisconsin Alumni Res Found ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
AU4746096A (en) * 1995-06-06 1996-12-24 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
CA3060669A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
MX2021014486A (es) * 2020-03-31 2022-01-04 Obi Pharma Inc Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo.

Also Published As

Publication number Publication date
IL314995A (en) 2024-10-01
US20250161186A1 (en) 2025-05-22
JP2025504247A (ja) 2025-02-06
WO2023156385A1 (en) 2023-08-24
CA3243198A1 (en) 2023-08-24
KR20240150786A (ko) 2024-10-16
TW202400223A (zh) 2024-01-01
EP4479012A1 (en) 2024-12-25
CO2024010938A2 (es) 2024-09-19
AR128515A1 (es) 2024-05-15
CN118829442A (zh) 2024-10-22
AU2023222384A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
CO2024010938A2 (es) Formulación líquida de toxina botulínica y uso de la misma
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
CR20190400A (es) Formulaciones de anticuerpo monoclonal anti-vrs
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
ECSP088962A (es) Nuevos herbicidas
AR108631A1 (es) Formulación de neurotoxinas
AR052247A1 (es) Un metodo y una composicion cosmetica par inhibir o controlar simultaneamente la transpiracion y/o mal olor axilar y mejorar o controlar el oscurecimiento de la piel
BR112022001678A2 (pt) Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
MXPA02007059A (es) Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado.
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
MX2019003611A (es) Formulaciones novedosas.
BR112022013204A2 (pt) Usos de uma composição e de uma preparação combinada
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
CO2020016014A2 (es) Formulación de proteína de fusión ctla4-ig
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
BR112022026699A2 (pt) Mecanismo de liberação de fragrâncias, método e usos do mesmo
CO2024010940A2 (es) Formulación líquida de toxina botulínica y uso de la misma
AR109277A1 (es) Composición y método para el tratamiento de las afecciones de la piel
MXPA02002117A (es) Uso de productos leguminosos para el tratamiento de agresiones externas.
MX2021015501A (es) Anticuerpos y metodos de uso.
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
MX2019008115A (es) Formulaciones topicas de detomidina.
BR112022021006A2 (pt) Métodos para reduzir ou prevenir a colonização de clostridioides difficile